A detailed history of Federated Hermes, Inc. transactions in Ocugen, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 383 shares of OCGN stock, worth $352. This represents 0.0% of its overall portfolio holdings.

Number of Shares
383
Holding current value
$352
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.98 - $1.95 $375 - $746
383 New
383 $0
Q2 2023

Aug 14, 2023

BUY
$0.45 - $0.88 $2,418 - $4,729
5,374 New
5,374 $2,000
Q4 2022

Feb 13, 2023

BUY
$1.11 - $1.87 $104,018 - $175,237
93,710 Added 907.6%
104,035 $135,000
Q3 2022

Nov 14, 2022

BUY
$1.75 - $3.1 $15,562 - $27,568
8,893 Added 621.02%
10,325 $19,000
Q2 2022

Aug 15, 2022

SELL
$1.83 - $3.45 $2,122 - $4,002
-1,160 Reduced 44.75%
1,432 $3,000
Q1 2022

May 13, 2022

BUY
$2.34 - $4.72 $6,065 - $12,234
2,592 New
2,592 $9,000

Others Institutions Holding OCGN

About Ocugen, Inc.


  • Ticker OCGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,566,000
  • Market Cap $199M
  • Description
  • Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...
More about OCGN
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.